Complexity in the tumour microenvironment: Cancer associated fibroblast gene expression patterns identify both common and unique features of tumour-stroma crosstalk across cancer types

Seminars in Cancer Biology

Volumn 35, Issue , 2015, Pages 96-106

  Gandellini, Paolo ^a   Andriani, Francesca ^a   Merlino, Giuseppe ^a   D'Aiuto, Francesca ^a   Roz, Luca ^a   Callari, Maurizio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Cancer associated fibroblasts (CAF); Gene expression; Inter disease; Lung cancer; Prostate cancer

Indexed keywords

BREAST CANCER; CANCER ASSOCIATED FIBROBLAST; CANCER TISSUE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; FIBROBLAST; GENE EXPRESSION; HUMAN; LUNG CANCER; MOLECULAR INTERACTION; PROSTATE CANCER; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; CELL COMMUNICATION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENETICS; META ANALYSIS (TOPIC); METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION; STROMA CELL;

BIOLOGICAL MARKER; TRANSCRIPTOME;

ANIMALS; BIOMARKERS; CELL COMMUNICATION; EXTRACELLULAR MATRIX; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; META-ANALYSIS AS TOPIC; NEOPLASMS; SIGNAL TRANSDUCTION; STROMAL CELLS; TRANSCRIPTOME; TUMOR MICROENVIRONMENT;

EID: 84948716649     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.08.008     Document Type: Review

References (127)

1. Egeblad M., Nakasone E.S., Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev. Cell 2010, 18:884-901. 10.1016/j.devcel.2010.05.012.
2. Pietras K., Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 2010, 316:1324-1331. 10.1016/j.yexcr.2010.02.045.
3. Polyak K., Haviv I., Campbell I.G. Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009, 25:30-38.
4. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322. 10.1016/j.ccr.2012.02.022.
5. Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 2013, 19:1423-1437. 10.1038/nm.3394.
6. Casey S.C., Amedei A., Aquilano K., Benencia F., Bhakta D., Boosani C.S., et al. Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin. Cancer Biol. 2015, 10.1016/j.semcancer.2015.02.007.
7. Östman A. The tumor microenvironment controls drug sensitivity. Nat. Med. 2012, 18:1332-1334. 10.1038/nm.2938.
8. Fong M.Y., Zhou W., Liu L., Alontaga A.Y., Chandra M., Ashby J., et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 2015, 17:183-194. 10.1038/ncb3094.
9. Webber J.P., Spary L.K., Sanders A.J., Chowdhury R., Jiang W.G., Steadman R., et al. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene 2015, 34:290-302. 10.1038/onc.2013.560.
10. Webber J., Yeung V., Clayton A. Extracellular vesicles as modulators of the cancer microenvironment. Semin. Cell Dev. Biol. 2015, 40:27-34. 10.1016/j.semcdb.2015.01.013.
11. Kohlhapp F.J., Mitra A.K., Lengyel E., Peter M.E. MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene 2015, 10.1038/onc.2015.89.
12. Wang T., Liu G., Wang R. The intercellular metabolic interplay between tumor and immune cells. Front. Immunol. 2014, 5:358. 10.3389/fimmu.2014.00358.
13. Elenbaas B., Weinberg R.A. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res. 2001, 264:169-184. 10.1006/excr.2000.5133.
14. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401. 10.1038/nrc1877.
15. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337. 10.1038/nature03096.
16. Orimo A., Weinberg R.A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006, 5:1597-1601.
17. Junttila M.R., de Sauvage F.J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013, 501:346-354. 10.1038/nature12626.
18. Sugimoto H., Mundel T.M., Kieran M.W., Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol. Ther. 2006, 5:1640-1646.
19. Madar S., Goldstein I., Rotter V. Cancer associated fibroblasts-more than meets the eye. Trends Mol. Med. 2013, 19:447-453. 10.1016/j.molmed.2013.05.004.
20. Augsten M. Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front. Oncol. 2014, 4:62. 10.3389/fonc.2014.00062.
21. Lo A., Wang L.-C.S., Scholler J., Monslow J., Avery D., Newick K., et al. Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Res. 2015, 10.1158/0008-5472.CAN-14-3041.
22. Ozdemir B.C., Pentcheva-Hoang T., Carstens J.L., Zheng X., Wu C.-C., Simpson T.R., et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014, 25:719-734. 10.1016/j.ccr.2014.04.005.
23. Rhim A.D., Oberstein P.E., Thomas D.H., Mirek E.T., Palermo C.F., Sastra S.A., et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 2014, 25:735-747. 10.1016/j.ccr.2014.04.021.
24. Öhlund D., Elyada E., Tuveson D. Fibroblast heterogeneity in the cancer wound. J. Exp. Med. 2014, 211:1503-1523. 10.1084/jem.20140692.
25. Valcz G., Sipos F., Tulassay Z., Molnar B., Yagi Y. Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology. J. Clin. Pathol. 2014, 67:1026-1031. 10.1136/jclinpath-2014-202561.
26. Paulsson J., Micke P. Prognostic relevance of cancer-associated fibroblasts in human cancer. Semin. Cancer Biol. 2014, 25:61-68. 10.1016/j.semcancer.2014.02.006.
27. Hinz B., Phan S.H., Thannickal V.J., Galli A., Bochaton-Piallat M.-L., Gabbiani G. The myofibroblast: one function, multiple origins. Am. J. Pathol. 2007, 170:1807-1816. 10.2353/ajpath.2007.070112.
28. Polyak K., Kalluri R. The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb. Perspect. Biol. 2010, 2:a003244. 10.1101/cshperspect.a003244.
29. Allinen M., Beroukhim R., Cai L., Brennan C., Lahti-Domenici J., Huang H., et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32. 10.1016/j.ccr.2004.06.010.
30. Peng Q., Zhao L., Hou Y., Sun Y., Wang L., Luo H., et al. Biological characteristics and genetic heterogeneity between carcinoma-associated fibroblasts and their paired normal fibroblasts in human breast cancer. PLoS One 2013, 8:e60321. 10.1371/journal.pone.0060321.
31. Bissell M.J., Radisky D. Putting tumours in context. Nat. Rev. Cancer 2001, 1:46-54. 10.1038/35094059.
32. Kojima Y., Acar A., Eaton E.N., Mellody K.T., Scheel C., Ben-Porath I., et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:20009-20014. 10.1073/pnas.1013805107.
33. Spaeth E.L., Dembinski J.L., Sasser A.K., Watson K., Klopp A., Hall B., et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009, 4:e4992. 10.1371/journal.pone.0004992.
34. Zeisberg E.M., Potenta S., Xie L., Zeisberg M., Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007, 67:10123-10128. 10.1158/0008-5472.CAN-07-3127.
35. Surowiak P., Murawa D., Materna V., Maciejczyk A., Pudelko M., Ciesla S., et al. Occurence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor. Anticancer Res 2007, 27:2917-2924.
36. Lee J., Fassnacht M., Nair S., Boczkowski D., Gilboa E. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res. 2005, 65:11156-11163. 10.1158/0008-5472.CAN-05-2805.
37. Park J.E., Lenter M.C., Zimmermann R.N., Garin-Chesa P., Old L.J., Rettig W.J. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J. Biol. Chem. 1999, 274:36505-36512.
38. Paulsson J., Sjöblom T., Micke P., Pontén F., Landberg G., Heldin C.-H., et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am. J. Pathol. 2009, 175:334-341. 10.2353/ajpath.2009.081030.
39. Ariga N., Sato E., Ohuchi N., Nagura H., Ohtani H. Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int. J. Cancer 2001, 95:67-72.
40. Jakowlew S.B. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 2006, 25:435-457. 10.1007/s10555-006-9006-2.
41. Bronzert D.A., Pantazis P., Antoniades H.N., Kasid A., Davidson N., Dickson R.B., et al. Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:5763-5767.
42. Hugo H.J., Lebret S., Tomaskovic-Crook E., Ahmed N., Blick T., Newgreen D.F., et al. Contribution of fibroblast and mast cell (afferent) and tumor (efferent) IL-6 effects within the tumor microenvironment. Cancer Microenviron. 2012, 10.1007/s12307-012-0098-7.
43. Mao Y., Keller E.T., Garfield D.H., Shen K., Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev. 2013, 32:303-315. 10.1007/s10555-012-9415-3.
44. Mercier I., Casimiro M.C., Wang C., Rosenberg A.L., Quong J., Minkeu A., et al. Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy. Cancer Biol. Ther. 2008, 7:1212-1225.
45. Martinez-Outschoorn U.E., Pavlides S., Whitaker-Menezes D., Daumer K.M., Milliman J.N., Chiavarina B., et al. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 2010, 9:2423-2433.
46. Koleske A.J., Baltimore D., Lisanti M.P. Reduction of caveolin and caveolae in oncogenically transformed cells. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:1381-1385.
47. Witkiewicz A.K., Dasgupta A., Sotgia F., Mercier I., Pestell R.G., Sabel M., et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am. J. Pathol. 2009, 174:2023-2034. 10.2353/ajpath.2009.080873.
48. Bonuccelli G., Whitaker-Menezes D., Castello-Cros R., Pavlides S., Pestell R.G., Fatatis A., et al. The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle 2010, 9:1960-1971.
49. Bibber B., Sinha G., Lobba A.R.M., Greco S.J., Rameshwar P. A review of stem cell translation and potential confounds by cancer stem cells. Stem Cells Int. 2013, 2013:241048. 10.1155/2013/241048.
50. Tsuyada A., Chow A., Wu J., Somlo G., Chu P., Loera S., et al. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res. 2012, 72:2768-2779. 10.1158/0008-5472.CAN-11-3567.
51. Park S.Y., Kim H.M., Koo J.S. Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer. Breast Cancer Res. Treat. 2015, 149:727-741. 10.1007/s10549-015-3291-9.
52. Bauer M., Su G., Casper C., He R., Rehrauer W., Friedl A. Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast. Oncogene 2010, 29:1732-1740. 10.1038/onc.2009.463.
53. Pennica D., Swanson T.A., Welsh J.W., Roy M.A., Lawrence D.A., Lee J., et al. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:14717-14722.
54. Kim Y.C., Clark R.J., Ranheim E.A., Alexander C.M. Wnt1 expression induces short-range and long-range cell recruitments that modify mammary tumor development and are not induced by a cell-autonomous beta-catenin effector. Cancer Res. 2008, 68:10145-10153. 10.1158/0008-5472.CAN-08-2992.
55. Finak G., Bertos N., Pepin F., Sadekova S., Souleimanova M., Zhao H., et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 2008, 14:518-527. 10.1038/nm1764.
56. Farmer P., Bonnefoi H., Anderle P., Cameron D., Wirapati P., Wirapati P., et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 2009, 15:68-74. 10.1038/nm.1908.
57. Singer C.F., Gschwantler-Kaulich D., Fink-Retter A., Haas C., Hudelist G., Czerwenka K., et al. Differential gene expression profile in breast cancer-derived stromal fibroblasts. Breast Cancer Res. Treat. 2008, 110:273-281. 10.1007/s10549-007-9725-2.
58. Ma X.-J., Dahiya S., Richardson E., Erlander M., Sgroi D.C. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 2009, 11:R7. 10.1186/bcr2222.
59. Tuxhorn J.A., Ayala G.E., Rowley D.R. Reactive stroma in prostate cancer progression. J. Urol. 2001, 166:2472-2483.
60. Tuxhorn J.A., Ayala G.E., Smith M.J., Smith V.C., Dang T.D., Rowley D.R. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin. Cancer Res. 2002, 8:2912-2923.
61. Taddei M.L., Giannoni E., Comito G., Chiarugi P. Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett. 2013, 341:80-96. 10.1016/j.canlet.2013.01.042.
62. Ayala G., Tuxhorn J.A., Wheeler T.M., Frolov A., Scardino P.T., Ohori M., et al. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin. Cancer Res. 2003, 9:4792-4801.
63. Jia Z., Rahmatpanah F.B., Chen X., Lernhardt W., Wang Y., Xia X.-Q., et al. Expression changes in the stroma of prostate cancer predict subsequent relapse. PLoS One 2012, 7:e41371. 10.1371/journal.pone.0041371.
64. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999, 59:5002-5011.
65. Fiaschi T., Marini A., Giannoni E., Taddei M.L., Gandellini P., De Donatis A., et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res. 2012, 72:5130-5140. 10.1158/0008-5472.CAN-12-1949.
66. Giannoni E., Bianchini F., Masieri L., Serni S., Torre E., Calorini L., et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010, 70:6945-6956. 10.1158/0008-5472.CAN-10-0785.
67. Giannoni E., Bianchini F., Calorini L., Chiarugi P. Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxid. Redox Signal. 2011, 14:2361-2371. 10.1089/ars.2010.3727.
68. Gandellini P., Giannoni E., Casamichele A., Taddei M.L., Callari M., Piovan C., et al. miR-205 hinders the malignant interplay between prostate cancer cells and associated fibroblasts. Antioxid. Redox Signal. 2014, 20:1045-1059. 10.1089/ars.2013.5292.
69. Gandellini P., Folini M., Longoni N., Pennati M., Binda M., Colecchia M., et al. miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res. 2009, 69:2287-2295. 10.1158/0008-5472.CAN-08-2894.
70. Mani S.A., Guo W., Liao M.-J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715. 10.1016/j.cell.2008.03.027.
71. Liao C.-P., Adisetiyo H., Liang M., Roy-Burman P. Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. Cancer Res. 2010, 70:7294-7303. 10.1158/0008-5472.CAN-09-3982.
72. Ashida S., Orloff M.S., Bebek G., Zhang L., Zheng P., Peehl D.M., et al. Integrated analysis reveals critical genomic regions in prostate tumor microenvironment associated with clinicopathologic phenotypes. Clin. Cancer Res. 2012, 18:1578-1587. 10.1158/1078-0432.CCR-11-2535.
73. Pascal L.E., Ai J., Vêncio R.Z.N., Vêncio E.F., Zhou Y., Page L.S., et al. Differential inductive signaling of CD90 prostate cancer-associated fibroblasts compared to normal tissue stromal mesenchyme cells. Cancer Microenviron. 2011, 4:51-59. 10.1007/s12307-010-0061-4.
74. Planche A., Bacac M., Provero P., Fusco C., Delorenzi M., Stehle J.-C., et al. Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer. PLoS One 2011, 6:e18640. 10.1371/journal.pone.0018640.
75. Doldi V., Callari M., Giannoni E., D'Aiuto F., Maffezzini M., Valdagni R., et al. Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activation. Oncotarget 2015, in press.
76. Dean J.P., Nelson P.S. Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis. Br. J. Cancer 2008, 98:245-249. 10.1038/sj.bjc.6604087.
77. Bianchi-Frias D., Vakar-Lopez F., Coleman I.M., Plymate S.R., Reed M.J., Nelson P.S. The effects of aging on the molecular and cellular composition of the prostate microenvironment. PLoS One 2010, 5. 10.1371/journal.pone.0012501.
78. Bavik C., Coleman I., Dean J.P., Knudsen B., Plymate S., Nelson P.S. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res. 2006, 66:794-802. 10.1158/0008-5472.CAN-05-1716.
79. Yang G., Rosen D.G., Zhang Z., Bast R.C., Mills G.B., Colacino J.A., et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:16472-16477. 10.1073/pnas.0605752103.
80. Liu D.-H., Chen Y.-M., Liu Y., Hao B.-S., Zhou B., Wu L., et al. Rb1 protects endothelial cells from hydrogen peroxide-induced cell senescence by modulating redox status. Biol. Pharm. Bull. 2011, 34:1072-1077.
81. Waghray M., Cui Z., Horowitz J.C., Subramanian I.M., Martinez F.J., Toews G.B., et al. Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. FASEB J. 2005, 19:854-856. 10.1096/fj.04-2882fje.
82. Taddei M.L., Cavallini L., Comito G., Giannoni E., Folini M., Marini A., et al. Senescent stroma promotes prostate cancer progression: the role of miR-210. Mol. Oncol. 2014, 8:1729-1746. 10.1016/j.molonc.2014.07.009.
83. Laberge R.-M., Sun Y., Orjalo A.V., Patil C.K., Freund A., Zhou L., et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat. Cell Biol. 2015, 17:1049-1061. 10.1038/ncb3195.
84. Bremnes R.M., Dønnem T., Al-Saad S., Al-Shibli K., Andersen S., Sirera R., et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J. Thorac. Oncol. 2011, 6:209-217. 10.1097/JTO.0b013e3181f8a1bd.
85. Kim S.-H., Choe C., Shin Y.-S., Jeon M.-J., Choi S.-J., Lee J., et al. Human lung cancer-associated fibroblasts enhance motility of non-small cell lung cancer cells in co-culture. Anticancer Res. 2013, 33:2001-2009.
86. Navab R., Strumpf D., Bandarchi B., Zhu C.-Q., Pintilie M., Ramnarine V.R., et al. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:7160-7165. 10.1073/pnas.1014506108.
87. Andriani F., Bertolini G., Caserini R., Bursomanno S., Gasparini P., Pastorino U., et al. Contribution of fibroblasts isolated from primary lung cancers and normal lung tissue to tumor growth. Proc. 102nd AACR Annu. Meet. 2011, 530.
88. Fromigué O., Louis K., Dayem M., Milanini J., Pages G., Tartare-Deckert S., et al. Gene expression profiling of normal human pulmonary fibroblasts following coculture with non-small-cell lung cancer cells reveals alterations related to matrix degradation, angiogenesis, cell growth and survival. Oncogene 2003, 22:8487-8497. 10.1038/sj.onc.1206918.
89. Vicent S., Sayles L.C., Vaka D., Khatri P., Gevaert O., Chen R., et al. Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo. Cancer Res. 2012, 72:5744-5756. 10.1158/0008-5472.CAN-12-1097.
90. Wald O., Izhar U., Amir G., Kirshberg S., Shlomai Z., Zamir G., et al. Interaction between neoplastic cells and cancer-associated fibroblasts through the CXCL12/CXCR4 axis: role in non-small cell lung cancer tumor proliferation. J. Thorac. Cardiovasc. Surg. 2011, 141:1503-1512. 10.1016/j.jtcvs.2010.11.056.
91. Bertolini G., D'Amico L., Moro M., Landoni E., Perego P., Miceli R., et al. Microenvironment modulated metastatic CD133+/CXCR4+/EpCAM- lung cancer initiating cells sustain tumor dissemination and correlate with poor prognosis. Cancer Res. 2015, in review.
92. Chen W.-J., Ho C.-C., Chang Y.-L., Chen H.-Y., Lin C.-A., Ling T.-Y., et al. Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat. Commun. 2014, 5:3472. 10.1038/ncomms4472.
93. Chang H.Y., Chi J.-T., Dudoit S., Bondre C., van de Rijn M., Botstein D., et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:12877-12882. 10.1073/pnas.162488599.
94. Kotaru C., Schoonover K.J., Trudeau J.B., Huynh M.-L., Zhou X., Hu H., et al. Regional fibroblast heterogeneity in the lung: implications for remodeling. Am. J. Respir. Crit. Care Med. 2006, 173:1208-1215. 10.1164/rccm.200508-1218OC.
95. Pechkovsky D.V., Hackett T.L., An S.S., Shaheen F., Murray L.A., Knight D.A. Human lung parenchyma but not proximal bronchi produces fibroblasts with enhanced TGF-beta signaling and alpha-SMA expression. Am. J. Respir. Cell Mol. Biol. 2010, 43:641-651. 10.1165/rcmb.2009-0318OC.
96. Tsukui T., Ueha S., Abe J., Hashimoto S., Shichino S., Shimaoka T., et al. Qualitative rather than quantitative changes are hallmarks of fibroblasts in bleomycin-induced pulmonary fibrosis. Am. J. Pathol. 2013, 183:758-773. 10.1016/j.ajpath.2013.06.005.
97. Pazolli E., Luo X., Brehm S., Carbery K., Chung J.-J., Prior J.L., et al. Senescent stromal-derived osteopontin promotes preneoplastic cell growth. Cancer Res. 2009, 69:1230-1239. 10.1158/0008-5472.CAN-08-2970.
98. Ishikawa S., Takenaka K., Yanagihara K., Miyahara R., Kawano Y., Otake Y., et al. Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer. Clin. Cancer Res. 2004, 10:6579-6585. 10.1158/1078-0432.CCR-04-0272.
99. Chen Y., Zou L., Zhang Y., Chen Y., Xing P., Yang W., et al. Transforming growth factor-β1 and α-smooth muscle actin in stromal fibroblasts are associated with a poor prognosis in patients with clinical stage I-IIIA nonsmall cell lung cancer after curative resection. Tumour Biol. 2014, 35:6707-6713. 10.1007/s13277-014-1908-y.
100. Nakao M., Ishii G., Nagai K., Kawase A., Kenmotsu H., Kon-No H., et al. Prognostic significance of carbonic anhydrase IX expression by cancer-associated fibroblasts in lung adenocarcinoma. Cancer 2009, 115:2732-2743. 10.1002/cncr.24303.
101. Ito M., Ishii G., Nagai K., Maeda R., Nakano Y., Ochiai A. Prognostic impact of cancer-associated stromal cells in patients with stage I lung adenocarcinoma. Chest 2012, 142:151-158. 10.1378/chest. 11-2458.
102. Neri S., Ishii G., Hashimoto H., Kuwata T., Nagai K., Date H., et al. Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma. Int. J. Cancer 2015, 10.1002/ijc.29464.
103. Chang H.Y., Sneddon J.B., Alizadeh A.A., Sood R., West R.B., Montgomery K., et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004, 2:E7. 10.1371/journal.pbio.0020007.
104. Edlund K., Lindskog C., Saito A., Berglund A., Pontén F., Göransson-Kultima H., et al. CD99 is a novel prognostic stromal marker in non-small cell lung cancer. Int. J. Cancer 2012, 131:2264-2273. 10.1002/ijc.27518.
105. Hwang R.F., Moore T., Arumugam T., Ramachandran V., Amos K.D., Rivera A., et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 2008, 68:918-926. 10.1158/0008-5472.CAN-07-5714.
106. Tjomsland V., Spångeus A., Välilä J., Sandström P., Borch K., Druid H., et al. Interleukin 1α sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neoplasia 2011, 13:664-675.
107. Walter K., Omura N., Hong S.-M., Griffith M., Vincent A., Borges M., et al. Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts. Clin. Cancer Res. 2010, 16:1781-1789. 10.1158/1078-0432.CCR-09-1913.
108. Garrido-Laguna I., Uson M., Rajeshkumar N.V., Tan A.C., de Oliveira E., Karikari C., et al. Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin. Cancer Res. 2011, 17:5793-5800. 10.1158/1078-0432.CCR-11-0341.
109. Erez N., Truitt M., Olson P., Arron S.T., Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010, 17:135-147. 10.1016/j.ccr.2009.12.041.
110. Berdiel-Acer M., Sanz-Pamplona R., Calon A., Cuadras D., Berenguer A., Sanjuan X., et al. Differences between CAFs and their paired NCF from adjacent colonic mucosa reveal functional heterogeneity of CAFs, providing prognostic information. Mol. Oncol. 2014, 8:1290-1305. 10.1016/j.molonc.2014.04.006.
111. Herrera M., Islam A.B.M.M.K., Herrera A., Martín P., García V., Silva J., et al. Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clin. Cancer Res. 2013, 19:5914-5926. 10.1158/1078-0432.CCR-13-0694.
112. Calon A., Lonardo E., Berenguer-Llergo A., Espinet E., Hernando-Momblona X., Iglesias M., et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 2015, 47:320-329. 10.1038/ng.3225.
113. Isella C., Terrasi A., Bellomo S.E., Petti C., Galatola G., Muratore A., et al. Stromal contribution to the colorectal cancer transcriptome. Nat. Genet. 2015, 47:312-319. 10.1038/ng.3224.
114. Lim K.P., Cirillo N., Hassona Y., Wei W., Thurlow J.K., Cheong S.C., et al. Fibroblast gene expression profile reflects the stage of tumour progression in oral squamous cell carcinoma. J. Pathol. 2011, 223:459-469. 10.1002/path.2841.
115. Zhang C., Fu L., Fu J., Hu L., Yang H., Rong T.-H., et al. Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clin. Cancer Res. 2009, 15:4017-4027. 10.1158/1078-0432.CCR-08-2824.
116. Raffaghello L., Vacca A., Pistoia V., Ribatti D. Cancer associated fibroblasts in hematological malignancies. Oncotarget 2015, 6:2589-2603.
117. Paggetti J., Haderk F., Seiffert M., Janji B., Distler U., Ammerlaan W., et al. Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood 2015, 10.1182/blood-2014-12-618025.
118. Du P., Kibbe W.A., Lin S.M. Lumi: a pipeline for processing Illumina microarray. Bioinforma 2008, 24:1547-1548.
119. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostat 2003, 4:249-264.
120. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3:Article3.
121. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:15545-15550.
122. Bergamaschi A., Tagliabue E., Sørlie T., Naume B., Triulzi T., Orlandi R., et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J. Pathol. 2008, 214:357-367. 10.1002/path.2278.
123. Triulzi T., Casalini P., Sandri M., Ratti M., Carcangiu M.L., Colombo M.P., et al. Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress. PLoS One 2013, 8:e56761. 10.1371/journal.pone.0056761.
124. Cohen J., Sznol M. Therapeutic combinations of immune-modulating antibodies in melanoma and beyond. Semin. Oncol. 2015, 42:488-494. 10.1053/j.seminoncol.2015.02.014.
125. Eggermont A.M.M., Maio M., Robert C. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. Semin. Oncol. 2015, 42:429-435. 10.1053/j.seminoncol.2015.02.010.
126. Reck M., Paz-Ares L. Immunologic checkpoint blockade in lung cancer. Semin. Oncol. 2015, 42:402-417. 10.1053/j.seminoncol.2015.02.013.
127. Sung K.E., Su X., Berthier E., Pehlke C., Friedl A., Beebe D.J. Understanding the impact of 2D and 3D fibroblast cultures on in vitro breast cancer models. PLoS One 2013, 8:e76373. 10.1371/journal.pone.0076373.